secwatch.observer — SEC 8-K summary
======================================

Issuer:     Barinthus Biotherapeutics plc. (BRNS)
CIK:        0001828185
Form:       8-K
Filed at:   2026-04-30T23:59:59+00:00
Accession:  0001828185-26-000018
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Barinthus Bio Q1 net loss narrows to $5.5M; merger with Clywedog on track
-------------------------------------------------------------------------

- Net loss of $5.5M ($0.14/shr) vs $19.6M ($0.49/shr) in Q1 2025.
- Cash $67.2M at March 31, 2026; post-merger cash runway expected through 2027.
- Merger with Clywedog expected mid-2026; combined company to trade as CLYD.
- Doug Swirsky appointed CFO effective May 1, 2026.
- VTP-1000 celiac trial data from multiple ascending dose portion expected H2 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1828185/000182818526000018/0001828185-26-000018-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1828185/000182818526000018/brns-20260430.htm
  HTML page:      https://secwatch.observer/filing/0001828185-26-000018

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer